Pine River Capital Management’s Sciclone Pharmaceuticals SCLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
– Sell
-405,985
Closed -$3.98M – 168
2017
Q1
$3.98M Buy
405,985
+275,985
+212% +$2.76M 0.08% 88
2016
Q4
$1.4M Buy
+130,000
New +$1.3M 0.05% 124

Other funds holding SCLN

Pine River Capital Management's SCLN Position: Q2 2017 in Review

Pine River Capital Management sold out of Sciclone Pharmaceuticals (SCLN) in Q2 2017, closing a stake of 405,985 shares — an estimated $3.98M sold.

Pine River Capital Management first reported a position in SCLN in Q4 2016 and held it in 2 quarters. The position peaked at $3.98M in Q1 2017. 142 funds tracked by Wall St. Rank hold SCLN as of Q2 2017.

  • Pine River Capital Management reported no remaining Sciclone Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Pine River Capital Management sold 405,985 Sciclone Pharmaceuticals shares in Q2 2017, an estimated $3.98M.
  • Pine River Capital Management first reported a position in Sciclone Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Pine River Capital Management's Sciclone Pharmaceuticals position peaked at $3.98M in Q1 2017.
  • 142 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals as of Q2 2017.

Based on Pine River Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.